Economic TimesLean R·
Biocon clears path for cancer drug launch
Biocon on Wednesday said it has entered into a global settlement and license agreement with Genentech for breast cancer drug Pebrilzo, its biosimilar to the reference product Perjeta (Pertuzumab). The patent settlement agreement resolves all pending disputes between the two companies across multiple jurisdictions, including the US and Canada, the biopharmaceutical company said in a regulatory filing on WednesdayUnder the terms of the agreement, Biocon is cleared to launch Pebrilzo in the Europe…
Read at Economic Times →
